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PreviewsPGC-1: Looking behind
the Sweet Treat for Porphyria
Porphyrias are a group of genetic disorders caused
by mutations in enzymes of the heme biosynthesis
pathway. Acute attacks of porphyria, reputedly the
disease that incapacitated the British sovereign King
George III (see this Cell cover), are precipitated by
fasting and are treated by infusing heme or glucose,
although the underlying molecular mechanisms re-
main unclear. In this issue of Cell, Handschin et al.
(2005) reveal that a transcriptional coactivator called
PGC-1 is a key player in both induction of porphyria
by fasting and amelioration of the symptoms by glu-
cose treatment.
The porphyrin heme is the crucial iron bound prosthetic
group of hemoglobins that enables red blood cells to
carry oxygen. All nucleated cells require heme for pro-
duction of functional respiratory cytochrome proteins.
About 85% of heme biosynthesis takes place in ery-
throid cells, and this heme is destined for incorporation
into hemoglobins (reviewed in Kauppinen, 2005). Most
of the heme that is not produced in red blood cells is
made by the liver and then incorporated into various
heme proteins such as members of the cytochrome
P450 family.
De novo heme biosynthesis is carried out by the se-
quential actions of eight distinct enzymes (see Figure
1A). The first and rate-limiting step of the pathway is
catalyzed by the enzyme δ-aminolevulinic acid (ALA)
synthase (ALAS), which promotes condensation of gly-
cine and succinyl CoA to form ALA. Mammals have two
ALAS genes: the housekeeping gene ALAS-1 is ubiqui-
tously expressed, whereas ALAS-2 is specific to ery-
throid cells. Given that excess heme is toxic to cells, it
is not surprising that the heme biosynthetic pathway is
tightly regulated. For example, both the expression and
activity of ALAS-1 are inhibited by heme via feedback
mechanisms. In addition, heme biosynthesis can be
upregulated in response to an increase in demand, per-
haps best illustrated by the drug-induced increase in
the production of cytochrome P450 family members in
the liver, which metabolize drugs. Reflecting the require-
ment of cytochrome P450 proteins for heme, many drugs
concomitantly induce expression of the ALAS-1 gene
(Podvinec et al., 2004). Ironically, such drug-mediated
induction of ALAS-1 expression in turn can precipitate
a porphyria attack in susceptible individuals.
Porphyrias are caused by loss-of-function mutations
in any of the seven enzymes of the heme biosynthetic
pathway apart from ALAS-1 (Kauppinen, 2005). These
mutations lead to overproduction and accumulation of
different heme biosynthetic intermediates depending
on which enzyme is affected. Mutations in four of the
enzymes cause inducible hepatic porphyria (see Figure
1A), which is characterized by the occurrence of acute
attacks with symptoms including abdominal pain andneurological disturbances, accompanied by a dramatic
increase in production and excretion of porphyrin pre-
cursors such as ALA and porphobilinogen (Kauppinen,
2005). Acute attacks are often precipitated by drugs,
hormones, or fasting. They are treated by removal of
the precipitating agent, together with infusion of heme
and/or glucose (Anderson et al., 2005; Kauppinen,
2005). Although heme is known to inhibit its own syn-
thesis through negative feedback loops, the molecular
mechanisms that underlie the beneficial effects of glu-
cose and the precipitating effects of fasting are not
known.
In this issue of Cell, Spiegelman and colleagues report
that a transcriptional coactivator called PGC-1α (PPAR
γ coactivator 1α) holds the key to unraveling the mys-
tery of acute porphyria attacks, the disease that reput-
edly incapacitated the British sovereign King George III
and induced his episodes of “madness” (Handschin et
al., 2005; see the Cell cover). PGC-1α was originally
identified by the Spiegelman group from a cDNA library
derived from brown fat tissue. These investigators
showed that PGC-1α is a cofactor that interacts with
the nuclear receptor family member PPAR γ (reviewed
in Puigserver and Spiegelman, 2003). In response to
cold temperature, its expression is induced in key ther-
mogenic tissues such as brown fat and skeletal muscle.
In these locations, PGC-1α plays an important role in
adaptive thermogenesis by enhancing the activities of
specific transcription factors (including PPAR γ) that reg-
ulate the expression of UCP-1, a key molecule that un-
couples ATP synthesis from mitochondrial respiration,
resulting in heat production (Puigserver and Spiegel-
man, 2003).
At first glance, there does not seem to be much of a
link between the ability of PGC-1α to regulate energy
metabolism and its connection with the genetic disease
porphyria. Subsequent studies by the Spiegelman
group and others revealed that PGC-1α has another im-
portant function in energy homeostasis: the regulation
of gluconeogeneis in the liver (reviewed in Puigserver
and Spiegelman, 2003). The term gluconeogenesis re-
fers to the process of de novo synthesis of glucose
from noncarbohydrate precursors (such as pyruvate
and alanine) upon prolonged fasting. It takes place
principally in the liver and is essential for providing the
sugar needed for organs such as the brain. PGC-1α
expression in the liver is rapidly induced by fasting (see
Figure 1B); and this increase in PGC-1α in turn acti-
vates the gluconeogenic program by coactivating key
transcription factors that turn on genes encoding glu-
coneogenic enzymes (Puigserver and Spiegelman, 2003;
Puigserver et al., 2003).
Given that fasting is a powerful inducer of acute at-
tacks of porphyria and that PGC-1α is dramatically in-
duced in the liver upon fasting, Handschin et al. were
intrigued by the possibility that PGC-1α might mediate
ALAS-1 expression induced by fasting. Indeed, an ini-
tial time course analysis showed that liver ALAS-1 and
PGC-1α exhibited almost identical temporal patterns of
upregulation in response to fasting. The authors then
Cell
488Figure 1. Insights into the Cause and Treat-
ment of Porphyria
(A) The heme biosynthetic pathway. Abbre-
viations for intermediates: ALA, δ-amino-
levulinic acid; PBG, porphobilinogen; HMB,
hydroxymethylbilane; Uro-P, Uroporphyrino-
gen; Copro-P, Coproporphyrinogen; Proto-P,
Protoporphyrinogen. Abbreviations for en-
zymes: ALAS, ALA synthase; ALAD, ALA de-
hydratase; PBGD, PBG deaminase; CPO,
Copro-P oxidase; PPO, Proto-P oxidase;
and FC, Ferrochelatase. The rate-limiting
enzyme ALAS is depicted in blue. The four
enzymes affected in inducible hepatic por-
phyrias are depicted in red. The asterisks in-
dicate enzymes that are inhibited by chemi-
cals used for inducing chemical porphyria.
Two other enzymes of the pathway are
Uro-P synthase and Uro-P decarboxylase
(not shown).
(B) PGC-1α regulates expression of the
ALAS-1 gene in response to fasting. Fasting
activates PGC-1α expression in the liver
through the cAMP/CREB pathway (reviewed
in Puigserver and Spiegelman, 2003). PGC-1α (red ovals) then binds to and coactivates the transcription factors NRF-1 and FOXO1, greatly
enhancing ALAS-1 expression (thick blue arrow). Glucose administration and the subsequent increase in insulin reverses this effect (1) by
antagonizing the induction of PGC-1α expression and (2) by disrupting the interaction of PGC-1α with FOXO1 (through promoting phosphory-
lation of FOXO1 by the Akt kinase). The promoter of the ALAS-1 gene also contains cAMP response elements (Giono et al., 2001) and thus
could be subjected to direct regulation by the cAMP/CREB pathway upon fasting, an effect that would also be antagonized by glucose
(not shown).used an adenovirus-based system to ectopically ex-
press PGC-1α in either cultured cells in vitro or in rat
liver in vivo. They then showed that in all cases ectopic
expression of PGC-1α markedly increased the produc-
tion of ALAS-1 mRNA. Interestingly, none of the other
genes of the heme biosynthetic pathway were induced
by PGC-1α. To further probe the role of endogenous
PGC-1α in ALAS-1 expression, Handschin et al. iso-
lated primary hepatocytes from either wild-type mice
or those lacking PGC-1α and treated them with a cock-
tail of hormones to mimic fasting. They found that
whereas the hormone cocktail markedly induced ex-
pression of ALAS-1 in wild-type cells, induction was
blunted in PGC-1α-deficient cells. Notably, lack of
PGC-1α also blunted the induction of gluconeogenic
genes, which are known to be regulated by PGC-1α.
These data clearly suggest an important role for
PGC-1α in ALAS-1 expression. Thus, the authors turned
to the promoter of ALAS-1 to further dissect how PGC-
1α exerts its effects. Inspection of known elements in
the ALAS-1 promoter revealed several informative fea-
tures: a region comprising two binding sites for the
transcription factor NRF-1 (Braidotti et al., 1993) and
a region containing the insulin-response element (see
Figure 1B). The insulin-response element is important
for insulin-mediated inhibition of ALAS-1, but the tran-
scription factor that binds to this region has remained
elusive (Scassa et al., 2004). Interestingly, previous
studies from the Spiegelman group have shown that
PGC-1α can act as a coactivator of NRF-1 during, for
example, mitochondrial biogenesis. Furthermore, yet
another transcription factor called FOXO1 interacts
with PGC-1α to activate gluconeogenic genes, and this
interaction is disrupted by insulin, which promotes
phosphorylation of FOXO1 by the Akt kinase (Puigserver
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fnd Spiegelman, 2003; Puigserver et al., 2003). Thus, it
s conceivable that PGC-1α could regulate the ALAS-1
romoter through two nonexclusive mechanisms. In the
irst, PGC-1α interacts with and coactivates NRF-1
ound at the NRF-1 sites, an action that is presumably
nsulin insensitive. In the second, PGC-1α interacts
ith and potentiates the activity of FOXO1, which binds
o the insulin-response element; this interaction can be
isrupted by insulin signaling. Using a variety of molec-
lar approaches—chromatin immunoprecipitation, gel-
hift and reporter assays, as well as mutagenesis
nalyses of regulatory elements—the authors convinc-
ngly document that this is indeed the case (see Fig-
re 1B).
To prove the crucial part played by PGC-1α in the
etabolic regulation of ALAS-1 in vivo, Handschin et
l. generated mice with a liver-specific deficiency in
GC-1α. As expected, fasting induced expression of
LAS-1 as well as PGC-1α in the liver of wild-type ani-
als. In animals with liver-specific PGC-1α deficiency,
owever, PGC-1α expression was ablated and, impor-
antly, the induction of ALAS-1 expression in the liver
as blunted. A similar effect was observed for gluco-
eogenic genes that depend on PGC-1α for induction
f their expression. The authors also examined the in-
uction of ALAS-1 expression by the drug phenobarbi-
al and found that the drug increased the production of
iver ALAS-1mRNA to a similar extent in both wild-type
nd PGC-1α-deficient animals. As the effect of pheno-
arbital is mediated by the nuclear receptors PXR and
AR (Podvinec et al., 2004), this result suggests that
hese receptors do not require PGC-1α for activation of
LAS-1.
Having demonstrated a critical role of PGC-1α in
asting-induced expression of ALAS-1, the authors
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489probed its functional relevance in porphyria using a
chemical model of this disease. Mice were treated with
chemicals such as lead that inhibit specific enzymes of
the heme biosynthetic pathway (see Figure 1A) result-
ing in “priming,” a condition that mimics the partial loss
of function in heme biosynthesis seen in genetic por-
phyria. Chemical treatment was combined with fasting
to precipitate a “porphyria attack” in mice. In a gain-
of-function experiment, overexpression of PGC-1α by
virus-mediated transduction, in combination with fast-
ing and chemical treatment, led to a dramatic increase
in expression of ALAS-1. Plasma levels of the porphyrin
precursors ALA and PBG were dramatically increased
in these animals, to levels comparable to those seen
in genetic mouse models of porphyria (Lindberg et al.,
1996). Thus, ectopic expression of PGC-1α in conjunc-
tion with fasting and chemical treatment created a
“porphyria attack” in otherwise normal animals. In con-
trast, wild-type animals subjected to the same fasting
and chemical regimen but in the absence of ectopic
PGC-1α exhibited a moderate increase in ALAS-1
mRNA and in porphyrin precursors such as ALA. Re-
markably, this moderate increase in ALAS-1 and in
heme precursors was completely ablated in animals
with liver-specific deletion of PGC-1α, suggesting that
these animals are protected from the milder “porphyria-
like” symptoms induced by the combined fasting and
chemical treatment. Taken together, the gain- and loss-
of-function experiments strongly indicate that PGC-1α
is a key factor that mediates the expression of ALAS-1
during porphyria attacks.
Short of directly examining the effects of PGC-1α
loss in a genetic mouse model of porphyria, the study
by Handschin et al. nevertheless clearly indicates that
PGC-1α is the culprit behind the precipitation of por-
phyria attacks by fasting. Thus, fasting induces expres-
sion in the liver of PGC-1α, which then acts as a power-
ful coactivator for the transcription factors NRF-1 and
FOXO1, resulting in enhanced ALAS-1 expression and
an increased risk of a porphyria attack (see Figure 1B).
Glucose administration, together with the resulting sec-
ondary increase in insulin, ameliorates this risk through
two independent mechanisms: first, by directly antago-
nizing the induction of PGC-1α expression and second,
by reducing the association between PGC-1α and
FOXO1 (see Figure 1B).
Given that the power of the sweet treat for porphyria
lies in the ability of glucose to tame PGC-1α, one could
envisage alternative (less calorific) treatments that
could target PGC-1α in the liver directly by, for exam-
ple, modulating its expression, activity, or its interaction
with relevant transcription factors. Although the devel-
opment of such therapeutics lies in the future, the new
study by Handschin et al. represents a vivid example of
an initial endeavor in a seemingly unrelated research
area (adipocyte metabolism) that has yielded therapeu-
tic insights into a human disease (porphyria). No doubt,
future studies will use mouse genetic models of por-
phyria (Lindberg et al., 1996) to directly examine the
function of PGC-1α. It will also be intriguing to test
whether loss of PGC-1α would sufficiently dampen the
overall activity of the ALAS-1 promoter such that this loss
might offer protection from attacks induced by drugssuch as phenobarbital despite the fact that these drugs
activate ALAS-1 in a PGC-1α-independent manner.
Dangsheng Li
Cell Press
1100 Massachusetts Avenue
Cambridge, Massachusetts 02138
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